Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: A comparative study

Haemophilia

Volumn 21, Issue 2, 2015, Pages 204-209

  Morfini, M ^a   Marchesini, E ^b   Paladino, E ^a   Santoro, C ^c   Zanon, E ^d   Iorio, A ^e  

^a University Hospital   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Factor VIII; Haemophilia; Half life; Pharmacokinetics; Switching

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HETERODIMER; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BOLUS INJECTION; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SUBSTITUTION; ELIMINATION HALF-LIFE; HEMOPHILIA A; HUMAN; PLASMA; PRIORITY JOURNAL; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; MALE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; FACTOR VIII; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923055892     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12550     Document Type: Article

References (28)

1. Gilbert MS. Musculoskeletal complications of haemophilia: the joint. Haemophilia 2000; 6(Suppl. 1): 34-7.
2. Blanchette VS. Prophylaxis in the haemophilia population. Haemophilia 2010; 16(Suppl. 5): 181-8.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 9: 535-44.
4. Santagostino E, Mannucci PM, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
5. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2-8.
6. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
7. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005; 11: 571-82.
8. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77(Suppl.): 3-132.
9. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
10. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
11. Messori A, Longo G, Morfini M et al. Individualization of factor VIII dosage. J Clin Hosp Pharm 1984; 9: 95-103.
12. Messori A, Longo G, Matucci M, Morfini M, Ferrini PL. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987; 13: 365-80.
13. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 51: 247-52.
14. Björkman S. Evaluation of the TCI Works Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia 2011; 17: 239-40.
15. EMA/CHMP/BPWP/144533/2009. Committee for medicinal products for human use (CHMP)-Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf 2011. Accessed August 2 2014.
16. Morfini M, Longo G, Messori A, Lee M, White G, Mannucci P. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). Thromb Haemost 1992; 68: 433-5.
17. White GC, 2nd, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
18. Fijnvandraat K, Berntorp E, ten Cate JW et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
19. Kessler CM, Gill JC, White GC, 2nd et al. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia 2005; 11: 84-91.
20. Di Paola J, Smith MP, Klamroth R et al. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007; 13: 124-30.
21. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990; 323: 1800-5.
22. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65: 253-9.
23. Morfini M, Mannucci PM, Tenconi PM et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 1993; 70: 270-2.
24. Vlot AJ, Koppelman SJ, Meijers JC et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
25. Lin Y, Yang X, Chevrier MC et al. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
26. Ofosu FA, Tse H, Naqvi A, Bhakta H, Song Y. The fraction of recombinant factor VIII:Ag unable to bind von Willebrandfactor has no FVIII coagulant activity: studies in vitro. Haemophilia 2012; 18: 917-25.
27. Kaveri SV, Dasgupta S, Andre S et al. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia 2007; 13(Suppl. 5): 61-4.
28. Dasgupta S, Repessé Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.